MX2019008535A - Agonista del ppar gamma para el tratamiento de la enfermedad de huntington. - Google Patents

Agonista del ppar gamma para el tratamiento de la enfermedad de huntington.

Info

Publication number
MX2019008535A
MX2019008535A MX2019008535A MX2019008535A MX2019008535A MX 2019008535 A MX2019008535 A MX 2019008535A MX 2019008535 A MX2019008535 A MX 2019008535A MX 2019008535 A MX2019008535 A MX 2019008535A MX 2019008535 A MX2019008535 A MX 2019008535A
Authority
MX
Mexico
Prior art keywords
pparï
huntington
disease
treatment
agonist
Prior art date
Application number
MX2019008535A
Other languages
English (en)
Inventor
Steinman Lawrence
Finck Barbara
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of MX2019008535A publication Critical patent/MX2019008535A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Metodos de tratamiento de la enfermedad de Huntington o de los sintomas de la misma con agonistas de PPAR? y, en particular, el compuesto de formula (I) conocido tambien como INT131: (ver fórmula).
MX2019008535A 2017-01-18 2018-01-18 Agonista del ppar gamma para el tratamiento de la enfermedad de huntington. MX2019008535A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762447741P 2017-01-18 2017-01-18
PCT/US2018/014240 WO2018136635A1 (en) 2017-01-18 2018-01-18 Pparϒ agonist for the treatment of huntington's disease

Publications (1)

Publication Number Publication Date
MX2019008535A true MX2019008535A (es) 2019-12-02

Family

ID=62908392

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008535A MX2019008535A (es) 2017-01-18 2018-01-18 Agonista del ppar gamma para el tratamiento de la enfermedad de huntington.

Country Status (13)

Country Link
US (1) US20190350918A1 (es)
EP (1) EP3570841A4 (es)
JP (1) JP2020505448A (es)
KR (1) KR20190122664A (es)
CN (1) CN110461330A (es)
AU (1) AU2018210165A1 (es)
BR (1) BR112019014529A2 (es)
CA (1) CA3050104A1 (es)
EA (1) EA201991716A1 (es)
IL (1) IL268008A (es)
MX (1) MX2019008535A (es)
SG (1) SG11201906644YA (es)
WO (1) WO2018136635A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895541B2 (en) * 2002-09-04 2014-11-25 James A. Carnazza Methods for inhibiting the development of huntington's disease
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
EP1812378A2 (en) * 2004-10-13 2007-08-01 University of Connecticut Cannabinergic lipid ligands
WO2009097996A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
EP2448412B1 (en) * 2009-07-01 2019-05-01 JDS Therapeutics, LLC Chromium complexes as enhancers of brain glucose transporters
KR20160110395A (ko) * 2013-12-20 2016-09-21 테바 파마슈티컬 인더스트리즈 리미티드 헌팅턴병 진행을 지연시키기 위한 라퀴니모드의 용도

Also Published As

Publication number Publication date
IL268008A (en) 2019-09-26
EP3570841A4 (en) 2020-08-19
WO2018136635A1 (en) 2018-07-26
EP3570841A1 (en) 2019-11-27
US20190350918A1 (en) 2019-11-21
SG11201906644YA (en) 2019-08-27
JP2020505448A (ja) 2020-02-20
AU2018210165A1 (en) 2019-08-01
CA3050104A1 (en) 2018-07-26
CN110461330A (zh) 2019-11-15
KR20190122664A (ko) 2019-10-30
BR112019014529A2 (pt) 2020-02-27
EA201991716A1 (ru) 2020-02-04

Similar Documents

Publication Publication Date Title
PH12018501226A1 (en) Methods for treating huntingtons disease
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
PH12015502788A1 (en) Antibody formulations and methods
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
NZ763098A (en) Thiazolopyridine derivatives as gpr119 agonists
EA201890641A3 (ru) Стимуляторы sgc
MX2009009207A (es) Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.
WO2016061509A8 (en) Compositions and methods of treating muscular dystrophy
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
NZ763528A (en) Heterocyclic gpr119 agonist compounds
MX366765B (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
MX2020012800A (es) Cannabinoides y usos de los mismos.
MX2019001979A (es) Agonista de ppar? para el tratamiento de neoplasias hematicas.
MX2019008535A (es) Agonista del ppar gamma para el tratamiento de la enfermedad de huntington.
MX2018004296A (es) Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada.
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
BR112019003133A2 (pt) agonista de ppargama para o tratamento de distúrbios ósseos
WO2017095918A3 (en) Methods for treating cancer using rspo3 antagonists
MX2022007874A (es) Compuestos y derivados de hidroxiestilbeno sustituido, síntesis y usos de los mismos.
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
MX2019001981A (es) Agonista de ppary para el tratamiento de trastornos oseos.